<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04737408</url>
  </required_header>
  <id_info>
    <org_study_id>Aarhus University Hospital</org_study_id>
    <nct_id>NCT04737408</nct_id>
  </id_info>
  <brief_title>Influence of Intensive Lipid-lowering on FFRCT (The FLOW-PROMOTE Study)</brief_title>
  <acronym>FlowPromote</acronym>
  <official_title>Influence of Intensive Lipid-lowering With Statin and Ezetimib Prescription on Computed Tomography Derived Fractional Flow Reserve in Patients With Stable Chest Pain (The FLOW-PROMOTE Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bjarne Linde Noergaard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aarhus University Hospital Skejby</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The FLOW-PROMOTE Study is an investigator-initiated, Danish multicenter study of patients&#xD;
      with stable chest pain investigating whether lipid lowering is associated with recovery of&#xD;
      impaired coronary flow as assessed by CT derived fractional flow reserve (FFRCT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter study (4 centers in Denmark), including 120 patients with stable chest pain and&#xD;
      hemodynamically significant coronary artery disease as assessed by FFRCT. By using two lipid&#xD;
      lowering treatment strategies (&quot;usual&quot; vs &quot;intensive&quot; care) over 18 months, the effect on&#xD;
      coronary plaque regression and flow recovery are assessed from repeated CT angiograms with&#xD;
      plaque and FFRCT analyses at 9 and 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 13, 2020</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients are randomized 1:1 to two different lipid lowering medical treatment strategies</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open label design</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>18-month change in coronary flow</measure>
    <time_frame>18 months</time_frame>
    <description>Coronary flow will be assessed by repetitive FFRCT assessments (0,9 and 18 months)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>18-month change high risk coronary plaque volumes</measure>
    <time_frame>18 months</time_frame>
    <description>Will be assessed by measuring low attenuation coronary plaque (LAP) volumes at repetitive CT angiograms (0,9, and 18 months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>18-month change in high risk coronary plaque features</measure>
    <time_frame>18-months</time_frame>
    <description>Will be assessed by quantifying the proportion of lesions with positive remodeling at repetitive CT angiograms (0,9, and 18 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>18-month change in coronary vessel volumes</measure>
    <time_frame>18-months</time_frame>
    <description>Will be assessed by calculating the vessel volume relative to myocardial mass (V/M) ratio determined from repetitive CT angiograms (0,9, and 18 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>18-month change in indices of coronary inflammation</measure>
    <time_frame>18-months</time_frame>
    <description>Will be assessed by the pericoronary fat attenuation index (FAI) determined from repetitive CT angiograms (0,9, and 18 months).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Reproducibility assessment</measure>
    <time_frame>9-months</time_frame>
    <description>There will be performed 2 CTA investigations at the 9 month follow-up. Reproducibility assessment of CT derived FFR, plaque markers, FAI and V/M ratio will be performed by calculation of standard error of measurement and within-subject coefficient of variation.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>&quot;Usual care&quot;</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>&quot;Usual care&quot; prevention: atorvastatin 40 mg per day for 18 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>&quot;Intensive care&quot;</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>&quot;Intensive care&quot; prevention: rosuvastatin 40 mg + ezetimib 10 mg per day for 18 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 40mg</intervention_name>
    <description>Rosuvastatin 40 mg</description>
    <arm_group_label>&quot;Intensive care&quot;</arm_group_label>
    <arm_group_label>&quot;Usual care&quot;</arm_group_label>
    <other_name>Ezetimib 10mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Symptoms suggestive of stable coronary artery disease (CAD)&#xD;
&#xD;
          2. No known CAD&#xD;
&#xD;
          3. At least one coronary stenosis with &gt;49% lumen reduction determined by CT angiography&#xD;
&#xD;
          4. Sinus rhythm&#xD;
&#xD;
          5. At least one lesion with FFRCT &lt;0.81 (see below)&#xD;
&#xD;
          6. Life expectancy &gt;3 years&#xD;
&#xD;
          7. Fertile women must use safe contraception throughout the study period&#xD;
&#xD;
          8. Signed informed consent&#xD;
&#xD;
        5. LDL cholesterol &gt;2.0 mM (patients already on lipid lowering medical therapy &lt; 3 months&#xD;
        can be included if meeting all of the above mentioned criteria)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unstable angina&#xD;
&#xD;
          2. Known CAD&#xD;
&#xD;
          3. Body mass index &gt;40&#xD;
&#xD;
          4. Allergy to iodinated contrast media&#xD;
&#xD;
          5. Known statin intolerance&#xD;
&#xD;
          6. Poor coronary CT angiography image quality inadequate for FFRCT calculation&#xD;
             (determined by core-laboratory)&#xD;
&#xD;
          7. Significant left main coronary artery (stenosis &gt;49%) or three-vessel CAD determined&#xD;
             by coronary CT angiography leading to direct referral to ICA&#xD;
&#xD;
          8. FFRCT &lt;0.81 over the left main coronary artery or the proximal left anterior&#xD;
             descendens artery (LAD) segment, or &lt;0.76 over the mid-LAD, proximal circumflex, right&#xD;
             coronary artery or intermediate coronary segments&#xD;
&#xD;
          9. Pregnancy (women with age &gt;45 will be screened for pregnancy)&#xD;
&#xD;
         10. Moderate to severe liver failure&#xD;
&#xD;
         11. Estimated glomerular filtration rate (eGFR) &lt; 60 ml/min&#xD;
&#xD;
         12. Participation in another trial&#xD;
&#xD;
         13. Does noes not wish to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bjarne L Noergaard, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bjarne L Noergaard, MD, PhD</last_name>
    <phone>+4540136570</phone>
    <email>bnorgaard@dadlnet.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin B Mortensen, MD, PhD</last_name>
    <phone>+4523882155</phone>
    <email>martin.bodtker.mortensen@clin.au.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200 N</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bjarne L Noergaard, MD, PhD</last_name>
      <phone>+4540136570</phone>
      <email>bnorgaard@dadlnet.dk</email>
    </contact>
    <contact_backup>
      <last_name>Martin B Mortensen, MD, PhD</last_name>
      <phone>+4523882155</phone>
      <email>martin.bodtker.mortensen@clin.au.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Jesper M Jensen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southwestern Hospital Esbjerg</name>
      <address>
        <city>Esbjerg</city>
        <zip>6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niels-Peter R Sand, MD, PhD</last_name>
      <phone>+4528409148</phone>
      <email>npsand@webspeed.dk</email>
    </contact>
    <contact_backup>
      <last_name>Lone D Kristensen, MD</last_name>
      <phone>+4521422813</phone>
      <email>lone.dejbjerg@dadlnet.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Lillebaelt Hospital</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Busk, MD, PhD</last_name>
      <phone>+4522473224</phone>
      <email>martin.busk@rsyd.dk</email>
    </contact>
    <contact_backup>
      <last_name>Flemming H Steffensen, MD, PhD</last_name>
      <phone>+4551503862</phone>
      <email>flemming.hald@rsyd.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 28, 2021</study_first_submitted>
  <study_first_submitted_qc>February 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 3, 2021</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital Skejby</investigator_affiliation>
    <investigator_full_name>Bjarne Linde Noergaard</investigator_full_name>
    <investigator_title>Associate Professor, MD, PhD, FESC</investigator_title>
  </responsible_party>
  <keyword>coronary artery disease, fractional flow reserve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

